scholarly journals The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage

2007 ◽  
Vol 29 (5) ◽  
pp. 387-398 ◽  
Author(s):  
Wilma E. Mesker ◽  
Jan M. C. Junggeburt ◽  
Karoly Szuhai ◽  
Pieter de Heer ◽  
Hans Morreau ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Primary Tumor ◽  
Independent Study ◽  
Stage I ◽  
Individual Risk ◽  
Lymph Node Status ◽  
Cox Regression Analysis ◽  
Candidate Marker ◽  
Node Status

Background: Tumor staging insufficiently discriminates between colon cancer patients with poor and better prognosis. We have evaluated, for the primary tumor, if the carcinoma-percentage (CP), as a derivative from the carcinoma-stromal ratio, can be applied as a candidate marker to identify patients for adjuvant therapy. Methods: In a retrospective study of 63 patients with colon cancer (stage I–III, 1990–2001) the carcinoma-percentage of the primary tumor was estimated on routine H&E stained histological sections. Additionally these findings were validated in a second independent study of 59 patients (stage I–III, 1980–1992). (None of the patients had received preoperative chemo- or radiation therapy nor adjuvant chemotherapy.) Results: Of 122 analyzed patients 33 (27.0%) had a low CP and 89 (73.0%) a high CP. The analysis of mean survival revealed: overall-survival (OS) 2.13 years, disease-free- survival (DFS) 1.51 years for CP-low and OS 7.36 years, DFS 6.89 years for CP-high. Five-year survival rates for CP-low versus CP-high were respectively for OS: 15.2% and 73.0% and for DFS: 12.1% and 67.4%. High levels of significance were found (OS p < 0.0001, DFS p < 0.0001) with hazard ratio’s of 3.73 and 4.18. In a multivariate Cox regression analysis, CP remained an independent variable when adjusted for either stage or for tumor status and lymph-node status (OSp < 0.001, OSp < 0.001). Conclusions: The carcinoma-percentage in primary colon cancer is a factor to discriminate between patients with a poor and a better outcome of disease. This parameter is already available upon routine histological investigation and can, in addition to the TNM classification, be a candidate marker to further stratify into more individual risk groups.

Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis

2011 ◽  
Vol 18 (12) ◽  
pp. 3261-3270 ◽  
Author(s):  
Daniel J. Sargent ◽  
Murray B. Resnick ◽  
Michael O. Meyers ◽  
Atoussa Goldar-Najafi ◽  
Thomas Clancy ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Guanylyl Cyclase ◽  
Cancer Staging ◽  
Lymph Node Status ◽  
Guanylyl Cyclase C ◽  
Node Status

Prognostic Value of Venous Invasion Detected by Elastin Stain May Surpass Lymph Node Status in Colon Cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hye Jin Kim ◽  
Gyu-Seog Choi ◽  
An Na Seo ◽  
Jun Seok Park ◽  
Soo Yeun Park ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Prognostic Value ◽  
Venous Invasion ◽  
Lymph Node Status ◽  
Node Status

scholarly journals Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases

2017 ◽  
Vol 24 (8) ◽  
pp. 2113-2121 ◽  
Author(s):  
Lars Thomas Seeberg ◽  
Cathrine Brunborg ◽  
Anne Waage ◽  
Harald Hugenschmidt ◽  
Anne Renolen ◽  
...  
Keyword(s):  
Lymph Node ◽  
Liver Metastases ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Primary Tumor ◽  
Colorectal Liver Metastases ◽  
Lymph Node Status ◽  
Node Status

Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 575-575
Author(s):  
D. A. Mankoff ◽  
L. Dunnwald ◽  
J. Gralow ◽  
G. Ellis ◽  
H. Linden ◽  
...  
Keyword(s):  
Blood Flow ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Primary Tumor ◽  
Tumor Response ◽  
Locally Advanced ◽  
Lymph Node Status ◽  
Tumor Blood Flow ◽  
Node Status ◽  
Post Therapy

575 Background: Response to neoadjuvant therapy in the primary tumor and nodal metastasis predicts benefit to patients as shown in several large clinical trials. We have previously shown that changes in tumor blood flow (BF) measured by [15O]-water PET predict pathologic primary tumor response. We now test whether primary tumor blood flow changes also predict axillary nodal metastases response and post-therapy lymph node status among women with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy. Methds: Fifty-five women with a primary diagnosis of LABC underwent dynamic [15O]-water PET scans prior to and at midpoint of neoadjuvant chemotherapy. We evaluated associations between tumor BF changes and pathologic primary tumor response: categorized as complete (CR), partial (PR) or no response (NR). We also assessed the relationship between primary tumor BF changes and post-therapy axillary lymph node status, categorizing the high risk (HR) group as 4+ nodes with extracapsular extension (ECE, n=12) versus the lower risk (LR) group with either fewer than 4+ nodes or without ECE (n=43). Results: The median changes in BF versus tumor response were: CR = -77%, PR = -40%, and, NR = +20% (P = <0.001). For axillary node response, the median BF change among HR patients was +20% versus - 49% among LR patients (P = 0.004). Eight of 17 patients with an increase in tumor blood flow were HR whereas 4/38 patients with decreased tumor blood flow were HR (P = 0.002). Conclusions: Change in primary tumor blood flow over the course of neoadjuvant chemotherapy predicts pathologic response to treatment with a substantial decrease observed among CRs. An increase in primary tumor BF with treatment portends significant residual primary tumor and a nearly 50% chance of very high-risk nodal disease post-therapy. No significant financial relationships to disclose.

scholarly journals The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma

Cancer ◽  
2001 ◽  
Vol 91 (12) ◽  
pp. 2401-2408 ◽  
Author(s):  
Markwin G. Statius Muller ◽  
Paul A. M. van Leeuwen ◽  
Elly S. M de Lange-de Klerk ◽  
Paul J. van Diest ◽  
Rik Pijpers ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Clinical Outcome ◽  
Cutaneous Melanoma ◽  
Stage I ◽  
Lymph Node Status ◽  
Node Status ◽  
Sentinel Lymph Node Status
Sign in / Sign up

Export Citation Format

Share Document